Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 8/20 | 0.54 |
| ▸ | CCR2 | P41597 | 3/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27784064 | 0.98 | PLA2G10 (0.53) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL16599057 | 0.86 | DAO (0.53) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL30305558 | 0.84 | DAO (0.67) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL4327040 | 0.84 | DAO (0.52) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL2940271 | 0.84 | DAO (0.67) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL7670332 | 0.82 | DAO (0.70) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL4103400 | 0.82 | PLA2G10 (0.53) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL5570219 | 0.81 | PLA2G10 (0.51) | PLA2G10CCR2DAOSLC9A1MCL1 | |
| SCHEMBL2323444 | 0.81 | MCL1 (0.71) | PLA2G10DAOSLC9A1MCL1 | |
| SCHEMBL19691145 | 0.81 | PLA2G10 (0.51) | PLA2G10CCR2DAOSLC9A1MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117603188-A | Indole and quinoline skeleton-containing compound and application thereof | 苏州卫生职业技术学院 | 2024-02-27 | — | — | CN | disclosed |
| US-20230101819-A1 | SMYD Inhibitors | EPIZYME INC (US) | 2023-03-30 | — | — | US | disclosed |
| US-20210198252-A1 | SMYD INHIBITORS | EPIZYME INC (US) | 2021-07-01 | — | — | US | disclosed |
| US-20190322660-A1 | SMYD INHIBITORS | Epizyme, Inc. | 2019-10-24 | — | — | US | disclosed |
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | Epizyme, Inc. (US) | 2019-04-23 | — | — | US | disclosed |
| CN-108349949-A | N- substituted indole derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-20170355695-A1 | SMYD Inhibitors | Epizyme, Inc. (US) | 2017-12-14 | — | — | US | disclosed |
| CN-103201276-B | Indole derivatives | RICHTER GEDEON NYRT | 2015-02-25 | — | — | CN | disclosed |
| CN-103201276-A | Indole derivatives | RICHTER GEDEON NYRT | 2013-07-10 | — | — | CN | disclosed |
| US-20100166701-A1 | METHOD FOR TREATING RENAL CELL CARCINOMA USING GLYCOGENOLYSIS INHIBITORS | PARKER GLENDON JOHN | 2010-07-01 | — | — | US | disclosed |
| EP-0686148-A4 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO INC (US) | 1996-02-07 | — | — | EP | disclosed |
| EP-0686148-A1 | INHIBITORS OF HIV REVERSE TRANSCRIPTASE | MERCK & CO. INC. (US) | 1995-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266526-B2 | Substituted 1,2,3-triazoles as SMYD inhibitors for treating cancer | SMYD3, SMYD2, SNRPD3 | PLA2G10 4418/4885CCR2 4343/4885DAO 2022/4885 |
| US-20170355695-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | PLA2G10 3433/4885CCR2 4465/4885DAO 1624/4885 |
| US-20210198252-A1 | SMYD INHIBITORS | SMYD3, SMYD2, SMURF2 | PLA2G10 3432/4885CCR2 4467/4885DAO 1686/4885 |
| US-20190322660-A1 | SMYD INHIBITORS | SMYD2, SMYD3, SMURF2 | PLA2G10 3520/4885CCR2 3779/4885DAO 1694/4885 |
| US-20230101819-A1 | SMYD Inhibitors | SMYD3, SMYD2, SMURF2 | PLA2G10 3406/4885CCR2 4452/4885DAO 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.